Although recipients of unrelated cord blood can tolerate a greater degree of HLA-disparity than recipients of unrelated bone marrow, cell dose is also important. After an unsuccessful search for a bone marrow donor, and after initially dismissing a cord blood search because the patient was 52 kg, we used a different search strategy to identify an unrelated cord blood unit. This led to successful engraftment and transplantation for a patient with no bone marrow donor. Bone Marrow Transplantation (2000) 26, 585-586. Keywords: bone marrow transplantation; cord blood A significant amount of data is now accumulating with the use of unrelated cord blood donors for stem cell transplantation. One of the major risk factors for failed engraftment is an older or heavier patient, who therefore receives a smaller cell dose per kg. We recently adopted a different strategy for one of our patients, which has been successful.
A significant amount of data is now accumulating with the use of unrelated cord blood donors for stem cell transplantation. One of the major risk factors for failed engraftment is an older or heavier patient, who therefore receives a smaller cell dose per kg. We recently adopted a different strategy for one of our patients, which has been successful.
Case report
A 16-year-old boy presented with second bone marrow and third CNS relapse of ALL. He had originally been diagnosed with cALLA-positive ALL 9 years previously. He achieved third bone marrow and fourth CNS remission. However, an unrelated bone marrow donor search, both in Australia and overseas, had failed to produce a suitable donor. He was 52 kg in weight, and our standard policy at the time was not to search for cord blood donors for patients over 40 kg in weight. The major risk factor for failure to engraft, delayed engraftment and adverse events following transplant in heavier patients relates to inadequate cell dosage. We therefore initiated an unrelated cord blood search based on the size of the donor unit. The patient weighed 52 kg and, as we needed a cell dose of 2 × 10 7 cells/kg, we searched for a unit with at least 100 × 10 7 cells. This information was not easy to find. The Netcord data- base provides information on volume and total nucleated cell count. However, although the initial search request form has a place for volume and cell count, the bone marrow registries that have incorporated cord blood units into their existing search programmes do not always provide this information in the search result. We therefore requested further information on units that were over or close to 100 ml in volume or had a high cell count. Requests for high resolution typing were placed as further information suggested that the cell count was adequate. High resolution typing was performed on a total of 11 units. This process took 6 weeks.
The preferred unit had a nucleated cell count of 8.6 × 10 8 cells (1.68 × 10 7 /kg). The volume recorded on the Netcord search was 67 ml (this was only 46 ml of cord blood and 21 ml of CPD, G Kogler, personal communication), and the CD34 count was 3 × 10 6 cells (0.58 × 10 5 /kg). Highresolution typing performed at the cord blood centre confirmed the level of HLA-identity. The patient was HLA A2,25; B 39,51, DRB1 11011, 1305; DQ B1 0301/9. The donor unit was HLA A2,25; B 18,51, DRB1 11011, 1301; DQ B1 0301/9, 0603/14 (4/6 match). We therefore proceeded to transplantation. The patient had previously had craniospinal irradiation for his first CNS relapse, so he had not received any further radiotherapy subsequent to this. He also had reduced frequency of intrathecal chemotherapy because of local symptoms from lumbar puncture. Despite also receiving high-dose intravenous methotrexate, a lumbar puncture performed on day −22 showed some suspicious cells. A further lumbar puncture was performed on day −8 and clearly demonstrated infiltration with CNS leukaemia. Because of this, his conditioning regimen was intensified with escalation of the high-dose methylprednisolone. He received a total of 3.5 g of methylprednisolone (2.3 g/m 2 ) between days −7 and −1. Intrathecal cytarabine was given on day −1; the CSF had almost completely cleared by this stage. The rest of his conditioning followed the Eurocord protocol, with ATG 15 mg/kg daily from days −6 to −1 (total 90 mg/kg); TBI 1200 cGy in six doses over 3 days on days −6, 5 and 4, and melphalan, 140 mg/m 2 on day −1. GVHD prophylaxis was with CsA and methylprednisolone.
The patient's early transplant course was uncomplicated. He developed severe haemorrhagic cystitis, which hindered his platelet recovery. However he achieved a neutrophil count of 0.1, 0.5 and 1.0 × 10 9 /l on days +20, +27 and +29
and an unsupported platelet count of 20, 50 and 100 × 10 12 /l on days +84, +84 and +111. His prednisolone taper was temporarily reversed for a rash typical of GVHD on day +27, which had disappeared by day +32. The patient was discharged on day +43. He developed no further signs of GVHD and ceased prednisolone on day +139 and cyclosporin on day +191. Engraftment has been documented with tissue typing on days +42 and +149 demonstrating the donor HLA type only. He remains in haematological and CNS remission at 1 year post transplant and has just had his 18th birthday.
Discussion
The literature has several examples of unsuccessful or transiently successful engraftment in adult recipients of cord blood. Eurocord data for unrelated cord blood transplants for acute leukaemia demonstrates that cord blood recipients who receive more than 3.7 × 10 7 nucleated cells/kg have a significantly higher rate of engraftment than patients receiving lower doses. 1 In univariate survival analysis of the New York data, success of myeloid engraftment, time to myeloid engraftment and the occurrence of transplantation-related events is related to age, number of leucocytes per kg in the graft and HLA disparity. However, in the multivariate model only leucocyte dose per kg and HLA disparity, and not age, were significantly related to the success and timing of myeloid engraftment. 2 This led us to revise our policy of using a cut-off weight of 40 kg when considering whether or not a cord blood search should be initiated for a patient.
In heavier patients, where cell dose seems critical, it makes sense to select first on the basis of adequate cell number. The strategy of searching by cell number first has been shown to be successful in this case. Whether this strategy is equally applicable to lighter patients would depend on further analysis of the data. It may be that HLA-disparity, and so risk of GVHD, is still more important than cell dose given once a threshold cell count has been passed.
The search process would be easier if the initial search report from the bone marrow registries included information, such as cell count, which is available from the cord blood banks.
